Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 5, 8,
  • 9,
  • 7,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16 and
BMC Cancer201414:720

https://doi.org/10.1186/1471-2407-14-720

  • Received: 3 September 2014
  • Accepted: 18 September 2014
  • Published:

The original article was published in BMC Cancer 2014 14:503

Correction

After publication of this Research Article [1], we noted errors in Table 1, and in the rate of thromboembolic events (page 7). Specifically, in Table 1 the percentage of female and male patients were incorrectly given as 7% and 3% respectively. The correct figures are 48.6% female and 51.4% male (please see a corrected version of Table 1 below, and the Additional file 1). The correct rate of thromboembolic events is 3.49% (originally stated as 3.55%).
Table 1

Patient demographics

Characteristic

Value

Age, mean ± SD (years)

66.49 ± 11.77

Patients with solid tumours, mean (years)

65.76

Patients with lymphoma, mean (years)

68.59

Patients with myeloma, mean (years)

70.65

Female (%)

48.6

Male (%)

51.4

Hb, mean ± SD (g/dL)

9.59 ± 0.88

sBP, mean ± SD (mmHg)

125.75 ± 14.48

dBP, mean ± SD (mmHg)

74.18 ± 9.79

Malignancies, n (%)

2310 (100)

Solid tumours, n (%)

1838 (79.57)

Lymphoma, n (%)

301 (13.03)

Myeloma, n (%)

171 (7.40)

Height, mean ± SD (cm)

166.35 ± 8.72

Weight, mean ± SD (kg)

67.46 ± 14.23

BMI, mean ± SD (kg/m2)

24.33 ± 4.62

BMI body mass index, dBP diastolic blood pressure, Hb haemoglobin, sBP systolic blood pressure, SD standard deviation.

Notes

Declarations

Authors’ Affiliations

(1)
Centre Hospitalier Lyon Sud, Lyon, France
(2)
Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
(3)
Institut Bergonie, Bordeaux, France
(4)
Centre Hospitalier de Troyes, Troyes, France
(5)
Centre Hospitalier de Carcassonne, Carcassonne, France
(6)
Centre Hospitalier de Montauban, Montauban, France
(7)
Clinique Sainte Anne, Strasbourg, France
(8)
Polyclinique Montréal, Carcassonne, France
(9)
Clinique Pasteur, Evreux, France
(10)
Clinique Rambot-Provencale, Aix en Provence, France
(11)
Centre Hospitalier d’Aix en Provence, Aix en Provence, France
(12)
Centre Hospitalier Régional Universitaire de Tours, Tours, France
(13)
Clinique du Cap d’Or, La Seyne sur Mer, France
(14)
Centre Frédéric JOLLIOT, Rouen, France
(15)
Centre Hospitalier de Montbéliard, Montbeliard, France
(16)
Laboratoire HOSPIRA France, MeudonLa Foret, France

References

  1. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe L-M, Labourey J-L, Lepille D, Maloisel F, Mouysset J-L, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer. 2014, 14: 503-10.1186/1471-2407-14-503.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/720/prepub

Copyright

Advertisement